Cell therapy, also known as cellular therapy or cytotherapy, is a type of biotherapy used to develop therapeutic strategies and drugs based on living cells. Cell therapy refers to biological activities exerted by cellular material that would cause a preferred effect either in vitro or in vivo. Over the years, an increasing number and range of cell types suitable for exogenous administration have been identified, with healing activity proven in animal models for various disorders. In cell therapy, cell suspensions are inserted into the blood stream or into a tissue or organ with the potential that the injected cells would heal any injury that has happened or that is enduring.
Research on cell therapy is ongoing; however, numerous cell types have been developed into treatments as innovative cell therapies and considered for impending medical applications. Hematopoietic stem cell transplantation is the most commonly used cell therapy for the treatment of various blood cancers and hematologic conditions. Probable uses of cell therapies include treatment of autoimmune disease, cancers, infectious disease & urinary problems, rejuvenating injured cartilage in joints, fixing spinal cord injuries, improving weakened immune system, and improving patients with neurological disorders.
Presently, governments of developed as well as developing countries are engaged in research & development and commercialization of cell therapy products. Directing the cell therapy product into high potential and enough effective value market. This would be the beginning of new age technology to recognize, understand, and establish personalized medicine, thereby driving the cell therapy products market. However, unclear guidelines for the manufacture of cell therapy products, no specified clinical research procedure for establishing the efficacy of treatment, and side effects are factors hampering the growth of the market.
Cell therapy signifies a new standard of medicine and is precisely very significant and also very meaningful as the world’s growth engine in post-IT era. These products have applications in a large number of disorders. These include diseases of the nervous system and cancer. Other applications are cardiac disorders such as heart failure and myocardial infarction, diabetes mellitus, ailments of bones and joints, genetic disorders, and injuries of the skin and soft tissues.
The global cell therapy products market can be segmented based on technology, type of cell, source of cell, application, and end-user. In terms of type of cell, the market can be bifurcated into autologous and allogeneic. Based on technology, the global cell therapy products market can be classified into cell immortalization, somatic cell technology, genome editing technology, viral vector technology, three-dimensional technology, and cell plasticity technology. The viral vector technology segment can be categorized into ex vivo and in vivo gene modifications. In terms of source of cell, the market can be divided into bone marrow, induced pluripotent stem cells (iPSCs), adipose tissue, umbilical cord blood-derived cells, and neural stem cell. Based on application, the global cell therapy products market can be classified into gastrointestinal, musculoskeletal, neurological, wound care, cardiovascular, oncology, dermatology, and others. In terms of end-user, the market can be categorized into hospitals & specialty clinics, diagnostic centers, research institutes, regenerative medicine centers, and others.
In terms of region, the global cell therapy products market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America accounted for the dominant share of the global market in 2018 owing to high research and development activities and increase in adoption of cell therapy products in the region. In North America, development of new cell therapies is supported by significant funding by governments and other regulatory bodies. Asia Pacific is one of the fastest developing economies in the world. Government initiatives is the major factor propelling the market in the region. The Government of South Korea invested US$ 100 Bn in research and development in 2012. The Ministry of Health and Welfare launched Global Stem Cell and Regenerative Medicine Initiative and invested KRW 45 Bn in R&D (US$ 15 Bn) in 2011. The Ministry of Education and Science Technology invested KRW 40 Bn in 2011 and KRW 49 Bn in 2012 and supports transitional clinical research in the field of stem cell and regenerative medicine. Moreover, rise in awareness about cell therapy and its benefits augment the cell therapy products market in Asia Pacific.
Major players operating in the global cell therapy products market include NuVasive, Inc., PHARMICELL Co., Ltd., Stemedica Cell Technologies, Inc., Fibrocell Science, Inc., Anterogen. Co., Ltd., Osiris Therapeutics, Inc., JCR Pharmaceuticals Co. Ltd., Cellectis, Pluristem, and Advanced Tissue.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.